LYVE1 and neoplasm: CHR-6494 has been reported to inhibit tumor-associated angiogenesis [22]; hence, we examined tumor-associated vasculogenesis by staining MDA-MB-231 tumors for CD31 and LYVE-1 (Fig 4D).